The campaign invites customers to embrace the feeling of fall through elevated imagery, a fresh take on seasonal styling, rich textures, and beautiful fabrications.

PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- Today, Anthropologie, the global lifestyle brand, introduced its Fall 2026 fashion campaign, "Fall Is a Feeling," celebrating the season through elevated fabrics and relaxed silhouettes. The campaign explores the many ways to dress for fall, from easy layers and new takes on familiar shapes to the sweater dress, reimagined as a signature seasonal silhouette, inviting customers to play with proportion, texture, and personal style.

"Fall Is a Feeling is our autumn campaign inspired by the emotional shift that comes with the season, the transition from the energy and spontaneity of summer into something quieter, calmer, and more reflective. We wanted to capture that moment when the world seems to slow down: the air changes, the colors deepen, and we naturally begin to turn inward," said Jisoo Kang, Chief Creative Officer at Anthropologie. "Ultimately, we wanted the imagery to evoke that unmistakable feeling that fall has arrived: a change in nature, a change in rhythm, and a chance to pause, reflect, and begin again."

The September catalog unfolds in two chapters, each offering a distinct perspective on fall dressing. The first takes an easygoing approach through relaxed pant shapes, suede and leather jackets, cozy sweaters, sleep shorts, and unexpected pairings. The second chapter shifts focus to knitwear and the sweater dress, with refined silhouettes and luxurious fabrics.

"This season, we really focused on giving familiar fall pieces a fresh perspective, playing with proportion, unexpected fabrications, and beautiful textures," said Richa Srivastava, Chief Creative Officer of Design at Anthropologie. "Sweater dresses are another hero for us this fall. We really pushed beyond the expected with elevated shapes, beautiful yarns, and flattering seam details. They have the ease you want from knitwear, but still feel designed—throw one on, add a great boot, and done."

Featuring our most elevated fabrications to date, the Fall collection doubles down on the versatile, "only-at-Anthropologie" pieces our community adores. Suedes and leathers take center stage across both chapters—anchoring structured outerwear, modern footwear, and statement accessories to craft a wardrobe that feels inherently chic and current.

"This season is all about tactile luxury—rooted in cashmere sweaters, airy wools, and rich suedes and leathers," said Holly Thrasher, Chief Merchandising Officer, Women's, at Anthropologie. "Whether through contemporary accessories or adaptable layering pieces across various price points, we're giving our customer effortless new ways to curate a look that feels uniquely her own."

Beginning September 8, "Fall Is a Feeling" will come to life across Anthropologie's owned, paid, and connected-TV channels. Organic social storytelling across Instagram and TikTok will spotlight fall trends, styling inspiration, and wardrobe-building content featuring creators and in-house talent, including Head of Brand and Creative Styling, Kyla Flax, and Anthropologie's 5-star stylists.

In stores, styling parties led by Anthropologie's 5-star stylists will invite customers to experience the season's key looks and explore new ways to style them. Anthropologie's 5-star stylists are expert personal stylists who offer personalized, one-on-one guidance to help customers build a wardrobe that feels uniquely their own, from discovering new silhouettes and trends to finding fresh ways to style pieces they already love. The complimentary styling experience is available both in-store and virtually, giving customers expert advice wherever they shop.

The Fall 2026 collection is available beginning September 8 at anthropologie.com and in stores globally.

About Anthropologie

Anthropologie is a modern, design-led lifestyle brand spanning fashion, home, weddings, garden, and gifting, where joyful self-expression meets inspired living. We create immersive shopping experiences that spark a sense of discovery and inspire customers to feel confident, curious, and connected, both online and in-store. Our curated collections blend own-brand exclusives with best-in-market partners, offering timeless quality and trend-forward design that reflect how our customer lives, hosts, travels, and dresses today. As we've evolved, Anthropologie has become a destination for her full lifestyle, from wardrobe to home to wellness, while continuing to bring imagination, narrative-driven storytelling, and memorable experiences to every touchpoint, from TikTok styling tips to in-store moments. With a global footprint of more than 220 stores, Anthropologie is rooted in inclusiveness, creativity, and community, always meeting our customer where she is and inspiring her to explore, experience, and celebrate her life in new ways.

PR CONTACT:

Samantha Chulick

[email protected] 

SOURCE Anthropologie

Share this article

LEAP Program Recognized for Integrated Approach to Leadership Development, Employee Growth and Succession Planning

NASHVILLE, Tenn., Sept. 8, 2026 /PRNewswire/ -- Gresham Smith and the Center for Creative Leadership (CCL) have received the Gold Award in the Best Leadership Development Program category for the 2026 Brandon Hall Group HCM Excellence Awards. The recognition honors Gresham Smith's Leadership Evolution and Advancement Program (LEAP), a year-long experience designed to strengthen leadership effectiveness, expand perspectives, and build meaningful connections across the firm.

Developed with CCL, LEAP brings together leaders from across Gresham Smith for an integrated program that combines immersive in-person summits, collaborative small-group experiences, and targeted learning sessions centered on real-world leadership challenges. Throughout the year, participants deepen their leadership approach skills, while strengthening the relationships and alignment needed to lead successful teams and projects.

"Receiving a Gold award reflects what LEAP was built to do: develop leaders who can deliver today and strengthen our succession planning for the future," said Chief Operating Officer Peter Oram. "We want the right people in the right places, ready to step into leadership roles as their careers evolve. LEAP balances leadership development with a clearer understanding of how our firm operates, and it is strengthened by the support and active participation of our Management Team."

Often called the "Academy Awards of Human Capital Management," the Brandon Hall Group HCM Excellence Awards have recognized organizations that set the standard for excellence in human capital management. Thousands of entries were submitted for consideration this year and evaluated through Brandon Hall Group's published judging methodology by a panel of veteran, independent senior industry experts, along with Brandon Hall Group analysts and executives. Entries were assessed for business alignment, program design and delivery, adoption and innovation, and measurable impact.

The Gold award represents the highest level of recognition in the category and underscores LEAP's strength in pairing a high-quality learning experience with measurable outcomes.

LEAP is part of Gresham Smith's broader commitment to supporting employee growth and development at every stage of their careers. Through the firm's Build U program, employees have access to tools, resources and learning opportunities that empower personal and professional development. As employees transition into leadership roles, Gresham Smith offers development programs tailored to their level and experience to ensure ongoing support and growth.

In addition to LEAP, the firm developed Way to Lead, a series of monthly courses focused on personal development, leadership strategies, team dynamics and cultivating a strong workplace culture. For new and emerging leaders, The Blueprint for Supervisory Excellence is a six-month, cohort-based program designed to help participants build the skills and confidence to become effective supervisors. The firm's mentorship program pairs employees with experienced colleagues who provide guidance during leadership transitions, and new managers also have access to dedicated HR partners who provide coaching, answer questions and help leaders navigate challenges.

About Gresham Smith:

Gresham Smith is a premier architecture, engineering and consultancy services firm providing integrated, comprehensive solutions for private- and public-sector clients. With $354 million in annual gross revenue and 27 offices throughout the United States, our expertise encompasses eight strategic sectors: aviation, building engineering, healthcare, industrial, land planning, life and work places, transportation, and water and environment. Throughout all of our work, we focus on providing exceptional client experience and outcomes. Repeatedly recognized by Fast Company as one of the World's Most Innovative Companies and consistently listed as a "Best Place to Work," we are committed to delivering on our Core Purpose—to plan, design and consult to create healthy and thriving communities—through our brand promise of Genuine Ingenuity. Learn more at GreshamSmith.com.

SOURCE Gresham Smith

Share this article

Multi-year grants will tackle approaches to help address disparities in cancer outcomes and advance clinical trials to improve early cancer detection

PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) announced nearly $2 million in funding from the V Foundation for Cancer Research, a nonprofit that supports peer-reviewed cancer research. The grants were awarded to two research leaders advancing innovative approaches to detecting and treating cancer in children. Andrei Thomas-Tikhonenko, PhD, Chief of the Division of Cancer Pathobiology at CHOP, was awarded the $1 million V Foundation Pediatric All-Star Cancer Research Grant to develop a novel chimeric antigen receptor (CAR) T-cell therapy for children with T-cell acute lymphoblastic leukemia (T-ALL), an aggressive form of blood cancer.

Dr. Thomas-Tikhonenko and his team will investigate P2RX5, a promising target found on leukemia cells, using genetic and biological datasets, laboratory studies, and preclinical models to evaluate the safety and efficacy of P2RX5-targeted CAR T cells. The research could pave the way for a first-in-human clinical trial within the next several years and ultimately provide a more precise treatment option for children with relapsed or treatment-resistant T-ALL. Importantly, the work may also help address disparities in cancer outcomes, as P2RX5-positive leukemias are more prevalent among children of African and Hispanic ancestry.

Suzanne MacFarland, MD, an attending physician in the Cancer Center at CHOP and Director of its Cancer Predisposition Program received an $800,000 V Foundation Pediatric Translational Cancer Research Grant to study a blood-based "liquid biopsy" approach for children and young adults with Li-Fraumeni syndrome (LFS), a rare inherited condition associated with a significantly increased risk of developing cancer. In Dr. MacFarland's study, researchers will pilot the use of a blood-based assay to detect tumor DNA in the bloodstream to detect cancer earlier than current screening methods. This study will also assess how liquid biopsy testing affects patients and caregivers. This study will be the crucial first step to understand the feasibility of this screening method ahead of a larger national trial.

"These awards are advancing two powerful frontiers in pediatric cancer research, from developing more precise, potentially lifesaving immunotherapies for children with difficult-to-treat leukemia to pioneering blood-based approaches that could detect cancer earlier in those at highest genetic risk," said Susan L. Furth, MD, PhD, Executive Vice President and Chief Scientific Officer at CHOP. "Together, they bring us closer to a future where cancer care is more targeted, more equitable, and more effective for every child. We are grateful to the V Foundation for Cancer Research for their longstanding partnership and ongoing support of our work."

The V Foundation has awarded nearly $6 million in funding to CHOP since 2010 to support efforts and this year's announcement marks the largest award in a single year. The All-Star Cancer Research grant is designed to advance transformative, high-risk/high-reward childhood cancer projects, and is only awarded to previous V Foundation grant recipients. Dr. Thomas-Tikhonenko, received the V Foundation's Pediatric Translational Award twice: in 2011 for the project "Novel Therapeutic Targets in Pediatric Acute B-Lymphoblastic Leukemia" and again in 2018 for "Alternative Surface Epitopes in Pediatric Acute Lymphoblastic Leukemia." These two projects allowed the Thomas-Tikhonenko laboratory to join the Pediatric Immunotherapy Discovery and Development Network (PI-DDN) funded by the National Cancer Institute's Cancer Moonshot Initiative.

The Pediatric Translational Cancer Research grant supports research that moves promising cancer discoveries from the lab toward clinical trials and improved patient care.

"These awards are a testament to the ingenuity, dedication, and vision of Drs. Thomas-Tikhonenko and MacFarland, whose research is pushing the boundaries of what is possible in pediatric cancer care," said Kara Coleman, Vice President of Grants and Research at the V Foundation. "Their work exemplifies the power of scientific discovery to address some of the greatest challenges facing children and families, bringing us closer to more effective treatments, earlier detection, and better outcomes for future generations."

To learn more about CHOP's Cancer Center, visit https://www.chop.edu/centers-programs/cancer-center.

About Children's Hospital of Philadelphia

A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania, New Jersey and Delaware. CHOP also operates the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia, the Behavioral Health and Crisis Center (including a 24/7 Crisis Response Center) and the Center for Advanced Behavioral Healthcare, a mental health outpatient facility. Its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit https://www.chop.edu.

About the V Foundation for Cancer Research

The V Foundation for Cancer Research was founded in 1993 by ESPN and the late Jim Valvano, legendary North Carolina State University basketball coach, ESPN commentator and member of the Naismith Memorial Basketball Hall of Fame. The V Foundation has funded over $500 million in game-changing cancer research grants in North America through a competitive process strictly supervised by a world-class Scientific Advisory Committee. Because the V Foundation has an endowment to cover administrative expenses, 100% of direct donations is awarded to cancer research and programs. The V team is committed to funding the best scientists to accelerate Victory Over Cancer® and save lives. To learn more, visit v.org.

Kaitlyn Dvorin

Children's Hospital of Philadelphia

610-618-0542 (cell)

[email protected]

SOURCE Children's Hospital of Philadelphia

Share this article

Collaboration brings enterprise-scale AI to patient access across a national dermatology network to connect patients with timely care.

SAN FRANCISCO and NASHVILLE, Tenn., Sept. 8, 2026 /PRNewswire/ -- Parakeet Health, a healthcare AI company that is transforming patient engagement at enterprise scale, and Qualderm, a management services organization for a national physician-led skin care network, today announced a collaboration to expand patient access, strengthen care continuity and reconnect patients following cancellations, missed visits, and overdue follow-ups.

Qualderm supports nearly 160 practices across 17 states, spanning medical, surgical and cosmetic dermatology, skin cancer care, and plastic surgery. Qualderm understands small gaps in patient access can cause missed care, delays in treatment, and worsening of untreated conditions. Parakeet helps Qualderm identify those care opportunities by evaluating provider schedules to determine where appointments are available for patients requiring care.

The collaboration comes as demand for dermatology care continues to grow, clinical and administrative staffing remains constrained. A recent study found that patients in 15 major metropolitan areas wait an average of 36.5 days for a dermatology appointment, up 6% since 2022. "For national networks such as Qualderm, reconnecting patients who cancel or miss visits and quickly filling newly available appointments helps more patients receive timely care and stay connected to their care plans" said Blake Area, Chief Marketing and Digital Officer at Qualderm.

"Specialty care is where enterprise AI must prove that it can manage real operational complexity," said Jung Park, CEO and Co-founder of Parakeet Health. "Every practice has different services, providers, scheduling rules and patient needs. Our work with Qualderm shows how AI can function within that complexity by interpreting clinical intent, identifying available capacity and completing the action inside the existing workflow. The result is directly measurable in patient access, care continuity and effective use of existing clinical capacity."

About Parakeet Health

Parakeet Health is a conversational agentic platform that automates burdensome patient-access workflows, helping connect patients with booked appointments, reduce administrative burden and support continuity of care. Its platform, powered by large language models (LLMs), supports various patient-experience use cases by managing both inbound and outbound communications at scale.

Founded by an experienced team of healthcare and technology leaders from some of the most innovative companies, Parakeet is backed by Canvas Ventures, Blank Space Ventures, CoFound Partners, StoryHouse Ventures and many notable individual investors. Visit www.parakeethealth.com for more information.

SOURCE Parakeet Health

Share this article

Phase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival Benefit Versus Durvalumab Alone

Study Also Met Secondary Progression-Free Survival and Objective Response Rate Endpoints

THOUSAND OAKS, Calif., Sept. 8, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced landmark results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi® (durvalumab) compared to durvalumab alone. This study tested IMDELLTRA as a first-line maintenance treatment for people with extensive stage small cell lung cancer (ES-SCLC) whose disease had not progressed following initial treatment with durvalumab, platinum-based chemotherapy and etoposide. The study also demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and objective response rate (ORR) among patients treated with IMDELLTRA in combination with durvalumab.

Overall, the safety profile of IMDELLTRA in combination with durvalumab was consistent with the known safety profiles of the individual medicines. No new or unexpected safety signals were identified in DeLLphi-305. The study design included monitoring in a healthcare setting for 1 to 2 hours (6 to 8 hours in certain regions including Europe) following IMDELLTRA infusion on Cycle 1 Day 1 and Cycle 1 Day 8.

"IMDELLTRA has already revolutionized the standard of survival for patients with extensive stage small cell lung cancer whose disease progressed on or after prior treatment. These landmark results from DeLLphi-305 suggest IMDELLTRA will further revolutionize the standard for survival earlier in the treatment journey and meaningfully shift the treatment paradigm for people facing this devastating disease," said Jay Bradner, M.D., executive vice president, Research and Development, Artificial Intelligence and Data at Amgen. "Despite clinical advances, extensive stage small cell lung cancer remains one of the most aggressive and difficult-to-treat cancers, and substantial improvements in survival are rare, underscoring the importance of these findings."

This marks the first Phase 3 study including a Bispecific T-cell Engager (BiTE®) therapy to demonstrate an overall survival benefit in the first-line maintenance setting for ES-SCLC.

"Given the aggressive nature of small cell lung cancer, many patients quickly relapse on current therapy and never reach second-line treatment. These patients do not have time to wait, making substantial progress in the first-line setting critically important," said Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute. "In my career treating people with extensive stage small cell lung cancer, these are among the most compelling survival results I have seen, indicating the potential to reshape the natural history of small cell lung cancer. DeLLphi-305 represents an unprecedented milestone and suggests we may be entering a new era where meaningfully longer survival is possible for more patients."

Following the U.S. Food and Drug Administration (FDA) approval of IMDELLTRA for adults with ES-SCLC whose disease has progressed on or after platinum-based chemotherapy, the robust global DeLLphi clinical trial program has continued to evaluate its potential across earlier stages of disease and lines of treatment, both as a monotherapy and in combination regimens. Building on the DeLLphi-303 trial, which showed very encouraging efficacy and tolerability results for IMDELLTRA in combination with anti-PD-L1 checkpoint inhibitors in the treatment of first-line ES-SCLC, DeLLphi-305 was designed to evaluate IMDELLTRA earlier in the course of disease, where more patients with SCLC may have the opportunity to benefit.

SCLC is one of the most aggressive forms of lung cancer, accounting for approximately 13-15% of the more than 2.6 million lung cancer cases diagnosed worldwide each year.1-3 Despite advances in the treatment of ES-SCLC, outcomes remain poor, with a median survival of approximately one year from the start of first-line maintenance treatment and only about 40% of patients receiving second-line therapy.4-7

Amgen plans to present detailed data from DeLLphi-305 at an upcoming international medical congress and share it with regulatory authorities.

About the Phase 3 DeLLphi-305 Study

The DeLLphi-305 trial is sponsored by Amgen, with partial funding and durvalumab provided by AstraZeneca. It is a global Phase 3, randomized, open-label clinical trial evaluating the efficacy and safety of IMDELLTRA in combination with durvalumab compared to durvalumab alone as first-line maintenance treatment for patients with ES-SCLC who had not progressed following treatment with durvalumab, platinum-based chemotherapy and etoposide. Five hundred and sixty-three patients who completed initial treatment with durvalumab, platinum-based chemotherapy and etoposide were randomized 1:1 to receive either IMDELLTRA in combination with durvalumab or durvalumab alone until progression or unacceptable toxicity. Following IMDELLTRA infusion on Cycle 1 Day 1 and Cycle 1 Day 8, patients were monitored in a healthcare setting for 1 to 2 hours (6 to 8 hours in certain regions including Europe). The trial included patients with both treated and untreated asymptomatic brain metastases at baseline. The primary outcome measure of the trial is OS. Secondary endpoints include progression-free survival (PFS) and objective response rate (ORR).8

About Tarlatamab Clinical Trials 

Tarlatamab is being investigated in multiple studies including DeLLphi-303, a Phase 1b study investigating tarlatamab in combination with standard-of-care (SOC) therapies in first-line ES-SCLC; DeLLphi-304, a randomized Phase 3 study comparing tarlatamab monotherapy with SOC chemotherapy in second-line treatment of SCLC; DeLLphi-305, a randomized Phase 3 study comparing tarlatamab in combination with durvalumab vs. durvalumab alone as first-line maintenance treatment in ES-SCLC; DeLLphi-306, a randomized placebo-controlled Phase 3 study of tarlatamab following concurrent chemoradiotherapy in limited-stage SCLC; DeLLphi-308, a Phase 1b study evaluating subcutaneous tarlatamab in second-line or later ES-SCLC; DeLLphi-309, a Phase 2 study evaluating alternative intravenous dosing regimens with tarlatamab in second-line ES-SCLC; DeLLphi-310, a Phase 1b study of tarlatamab in combination with YL201 with or without durvalumab in patients with ES-SCLC; DeLLphi-311, a Phase 1b study of tarlatamab in combination with etakafusp alfa (AB248), a novel CD8+ T-cell selective interleukin-2 (IL-2), in patients with ES-SCLC; DeLLphi-312, a randomized Phase 3 study evaluating tarlatamab in combination with durvalumab, carboplatin and etoposide as an induction and maintenance therapy in first-line treatment of ES-SCLC; DeLLphi-313, a Phase 1b study of tarlatamab in combination with zocilurtatug pelitecan, a DLL3 targeting antibody drug conjugate, with and without durvalumab in patients with ES-SCLC, and DeLLphi-315, a Phase 3 study of subcutaneous tarlatamab in patients with second-line ES-SCLC.9

For more information, please visit www.tarlatamabclinicaltrials.com.

About IMDELLTRA® (tarlatamab-dlle) 

IMDELLTRA is a first-in-class targeted immunotherapy engineered by Amgen researchers to bind to both DLL3 on tumor cells and CD3 on T cells, thereby activating T cells to kill DLL3-expressing SCLC cells. This results in the formation of a cytolytic synapse with lysis of the cancer cell.10,11 DLL3 is a protein that is expressed on the surface of SCLC cells in ~85-96% of patients with SCLC, but is minimally expressed on healthy cells, making it an exciting target.12,13

U.S. INDICATION

IMDELLTRA® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. 

IMDELLTRA IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME

- Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving IMDELLTRA®. Initiate treatment with IMDELLTRA® using the step-up dosing schedule to reduce the incidence and severity of CRS. Withhold IMDELLTRA® until CRS resolves or permanently discontinue based on severity. 

- Neurologic toxicity and immune effector cell-associated neurotoxicity syndrome (ICANS), including life-threatening or fatal reactions, can occur in patients receiving IMDELLTRA®. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS, during treatment and treat promptly. Withhold IMDELLTRA® until ICANS resolves or permanently discontinue based on severity.

WARNINGS AND PRECAUTIONS

- Cytokine Release Syndrome (CRS): IMDELLTRA® can cause CRS including life-threatening or fatal reactions. In the pooled safety population, CRS occurred in 57% (268/473) of patients who received IMDELLTRA®, including 39% Grade 1, 15% Grade 2, 1.7% Grade 3 and 0.2% Grade 4. Recurrent CRS occurred in 24% of IMDELLTRA®-treated patients including 20% Grade 1 and 3.4% Grade 2; one patient experienced recurrent Grade 3.

Among the 268 patients who experienced CRS, 73% had CRS after the first dose, 60% had CRS after the second dose, and 15% had CRS following the third or later dose. Following the Cycle 1 Day 1, Day 8, Day 15 infusions, 24%, 8%, and 1% of patients experienced Grade ≥ 2 CRS, respectively. From Cycle 2 onwards, 1.5% of patients experienced Grade ≥ 2 CRS. Of the patients who experienced CRS, 31% received steroids and 10% required tocilizumab.

Leading Fertility Center Expands Access to Personalized Care as It Celebrates 10 Years and More Than 10,000 Pregnancies

DENVER, Sept. 8, 2026 /PRNewswire/ -- Spring Fertility, one of the nation's most innovative fertility providers, today announced the opening of its newest clinic in Denver, Colorado. As Spring Fertility celebrates 10 years of delivering exceptional clinical outcomes and a deeply personalized patient experience, the new location builds on the company's milestone of helping patients achieve more than 10,000 pregnancies. The clinic will be led by Medical Director Dr. Debra Minjarez, who previously spent more than 15 years as Medical Director of Colorado Center for Reproductive Medicine (CCRM), and Physician Dr. Natalia Grob, who previously practiced at Kindbody Denver and Conceptions Reproductive Associates of Colorado. It will begin accepting appointments on September 8, and is located at 1900 Lawrence Street.

"We're excited to bring Spring Fertility's personalized approach to care to Denver," said Dr. Debra Minjarez, Medical Director of Spring Fertility Denver. "Every patient has a unique story, and we're committed to delivering individualized treatment plans backed by cutting-edge science while ensuring every patient feels seen, heard, and supported throughout their journey."

More Than a Number: A Different Kind of Fertility Care

When Spring Fertility was founded ten years ago, the vision was simple but ambitious: to build the best fertility center in the world - a place where patients would have the highest possible chance of success and the most personalized, human experience.

Spring was created to fix what was missing in wrong fertility care: cookie-cutter protocols, limited transparency, and patients feeling like a case number. Every aspect of the patient experience was reimagined, from clinical protocols to communication, to create a model centered around individualized care and exceptional outcomes.

Unlike many clinics where patients feel like they're just another chart, Spring Fertility is known for its highly personalized care model. Patients have frequent, direct access to their physician and care team, with treatment protocols customized to their specific needs, not a one-size-fits-all template. The clinic's extended monitoring hours also offer greater flexibility for working professionals, with appointment times throughout the day instead of limited early morning windows.

Highly Individualized Treatment Plans

At the core of Spring Fertility's success is its highly individualized treatment plan, where medication doses are adjusted multiple times during the treatment cycle to adjust to the body's changing needs. Rather than simply offering conventional high dose regimens, Spring offers gentle stimulation, which is particularly suitable for women with lower ovarian reserve. Spring is built for your schedule, offering early morning and weekend appointments.

Access Made Easier with the Spring Promise

To increase access to fertility preservation, Spring Fertility offers the Spring Promise—a money back guarantee in addition to a pioneering payment plan that allows patients to freeze their eggs now and pay over time. With egg freezing often excluded from insurance coverage, the program is designed to remove financial barriers for people looking to preserve their options for the future.

"Having had the privilege of caring for patients in the Denver community, I'm excited to continue that work with Spring Fertility," said Dr. Natalia Grob, Physician at Spring Fertility Denver. "What drew me to Spring is its belief that exceptional medicine and a meaningful physician-patient relationship should go hand in hand. I'm proud to be part of a team bringing that approach to Denver."

About Spring Fertility

Spring Fertility is a national fertility center recognized for its cutting-edge science, individualized treatment, and empathetic care. With locations across New York, California, and Oregon, Spring has helped thousands of patients grow their families and preserve their fertility with integrity, innovation, and heart. As the company celebrates its 10th anniversary and more than 10,000 pregnancies, Spring continues its mission to provide best-in-class fertility care that puts patients at the center.

SOURCE Spring Fertility

Share this article

Powered by GOBEL's proprietary models built for patient data, Gratify fuses electronic medical record and CRM data so fundraisers can see where gratitude lives, understand what drives it, and engage patients with the care that relationship deserves.

TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- GOBEL today announced the launch of Gratify, a grateful patient intelligence platform built for hospitals, health system foundations, and healthcare fundraising organizations.

Gratify provides clinical fundraisers a dedicated, user-friendly platform that fuses electronic medical record (EMR) data and constituent relationship management (CRM) data with GOBEL's proprietary, healthcare-specific predictive models to give a comprehensive view of patient gratitude and philanthropic capacity and enable more effective prospect prioritization and qualification than ever before.

Gratify is built around three core capabilities:

- Gratitude made visible. Gratify combines clinical signals from the EMR with giving history and engagement from the CRM to create a unified Prospect Intelligence Profile for each potential donor. The Prospect Intelligence Profile derives patient gratitude from GOBEL's proprietary, AI-powered predictive models,  These models have been developed specifically for healthcare philanthropy, and trained on combined clinical and philanthropic records, rather than adapted from general nonprofit benchmarks.

- Existing fundraising tools built for multiple markets miss the unique insights that are essential for effective prospect identification in healthcare. Gratify is built and trained solely for healthcare.

- Gratitude and capacity, read together. Each Prospect Intelligence Profile includes a Gratify score to enable fundraisers to quickly see who is likely to give, and where a transformative gift is genuinely in reach.

- Every Prospect Intelligence Profile surfaces wealth capacity data, alongside the clinical and giving picture, allowing fundraisers to immediately see and understand every prospect.

- Gratify is not a black box – every profile includes an explainability layer detailing the specific factors contributing to each score, so fundraisers understand why a name appears on a list and what the relationship is built on.

- Smart engagement that increases gift officer capacity while leveraging the care experience. Gratify provides semi-automated, secure, and compliant communication workflows that leverage the clinician relationship and build on the best practices of strong grateful patient fundraising to scale prospect engagement. This innovation enables gift officers to qualify more prospects and spend more time moving relationships towards meaningful gifts.

Since its founding in 2011, GOBEL has believed that gratitude drives the decision to give, while capacity determines the level of the gift. Understanding both, for the right person at the right moment, is the heart of healthcare philanthropy. Gratitude lives in the clinical record. Capacity lives in the CRM and wealth screening data. Until now, no single solution brought these together for healthcare philanthropy.

"Gratitude drives the decision to give, but the only way you've been able to identify gratitude is through individual conversations with clinicians and friends. While this information is powerful, it's inefficient to acquire and impossible to scale. We have changed all of that with Gratify. Now you can instantly identify every person's level of gratitude with Gratify. Grateful patient fundraising will never be the same."

Chad Gobel, Founder and CEO, GOBEL

Gratify changes that by giving healthcare philanthropy teams a single platform to identify their best grateful patient prospects using GOBEL's proprietary analytics, combined with their own EMR and CRM data, and collaborate across the entire gift process from prospecting to donation.

"Gratitude has always been what healthcare fundraisers most needed to understand and had the least visibility into. Gift officer time is the scarcest resource in any foundation. When you know where gratitude lives before the first conversation, fundraisers show up at the right moment with the right prospects, and no meaningful gift is missed."

Steve MacLaughlin, Head of Product, GOBEL

Healthcare organizations interested in Gratify can learn more or request a demo at https://gobelgroup.com/technology/gratify/. GOBEL will demonstrate the platform at the Association for Healthcare Philanthropy International Conference, October 7 to 9.

About GOBEL

GOBEL is a leading healthcare philanthropy consulting and technology firm working with health care organizations to build and grow strong and sustainable fundraising programs at every level. GOBEL combines strategic consulting, training, services, and technology to help organizations optimize their fundraising operations and leverage the full philanthropic potential.

Media Contact

Greta Daniels

Senior Vice President, Sales and Marketing

[email protected]

SOURCE GOBEL

Share this article

The new PNC program elevates workplace banking with meaningful rewards and 

personalized financial support and education

PITTSBURGH, Sept. 8, 2026 /PRNewswire/ -- PNC Bank today announced the launch of PNC Workplace Advantage, a new workplace banking program designed to help employers enhance their benefit offerings while supporting employees' financial confidence and overall well-being. Part of PNC's broader Financial Wellness Solutions platform, PNC Workplace Advantage delivers banking rewards, financial education and personalized guidance through a dedicated team of financial wellness experts, helping employers provide a more modern and valuable experience for their workforce.

Designed for companies with 100 or more employees, PNC Workplace Advantage helps employers elevate their benefits strategy without adding administrative complexity. The program integrates seamlessly into the workplace, enabling employers to offer a financial wellness benefit through a trusted financial institution. In addition to enhanced banking rewards, employees have access to personalized financial guidance from dedicated financial wellness professionals, flexible access to banking services available virtually or onsite and financial education through live seminars and on-demand digital resources designed to support real-life financial decisions.

"This launch represents an important step in the evolution of our financial wellness offerings," said Kaley Keeley, head of Financial Wellness Solutions at PNC. "PNC Workplace Advantage builds on the momentum we've created across our solutions, delivering a more cohesive and impactful way to help employers support the financial well-being of their employees. Today's workforce is looking for practical benefits they can actually use, not added complexity. PNC Workplace Advantage cuts through the noise with tools, educational resources and rewards that are relevant, easy to access and focused on what matters most in their financial lives."

Through PNC Workplace Advantage, employees who open a qualifying PNC checking account and set up a qualifying direct deposit method through their employer, will be invited to enroll in PNC TotalRewards Silver Tier. This is a benefit level that is typically only available to customers who maintain at least $25,000 or more in deposits and investments.

As part of PNC Financial Wellness Solutions, PNC Workplace Advantage complements a comprehensive suite of offerings, including PNC EarnedIt, education benefits, PNC BeneFit Plus Health Savings and other Benefit Spending Accounts, retirement services and financial education. Together, these solutions give employers the flexibility to build a benefits strategy that aligns with the diverse financial needs of their workforce.

"Financial well-being has become a critical factor in attracting, engaging and retaining talent, yet many organizations are still looking for ways to provide meaningful support without adding complexity," said Alina Crisi-Wetherell, head of Affiliated Banking at PNC. "With PNC Workplace Advantage, we're offering employers a smarter way to support their workforce, delivering real value to employees while helping organizations strengthen employee engagement and long-term loyalty."

PNC Workplace Advantage reflects the evolution of PNC's workplace banking experience, going beyond traditional banking benefits to offer support that meets employees where they are, both at work and in their daily lives.

The launch of PNC Workplace Advantage reflects PNC's broader commitment to helping employers address the financial well-being of their workforce, informed by ongoing research, including PNC's annual Financial Wellness in the Workplace Report launching later this month, as well as client webinars and educational events designed to help employers navigate today's diverse workforce. For more information about PNC Workplace Advantage and PNC Financial Wellness Solutions, visit pnc.com/WorkplaceAdvantageEmployer.

PNC Bank, National Association, is a member of The PNC Financial Services Group, Inc. (NYSE: PNC). PNC is one of the largest diversified financial services institutions in the United States, organized around its customers and communities for strong relationships and local delivery of retail and business banking including a full range of lending products; specialized services for corporations and government entities, including corporate banking, real estate finance and asset-based lending; wealth management and asset management. For information about PNC, visit www.pnc.com.

CONTACT:

Darby Rowe

(717) 824-6314 

[email protected]

SOURCE PNC Bank

Share this article

DALLAS, Sept. 8, 2026 /PRNewswire/ -- VineBrook Homes Trust, Inc. ("VineBrook Homes" or the "Company") announced today it launched a tender offer (the "Offer") to purchase up to $30 million, or 909,090 shares, of its Class A common stock, par value $0.01 per share (the "Shares"), for cash at an offer price equal to $33.00 per Share (the "Offer Price"). The Offer is expected to expire at 5:00 P.M., Eastern Time, on October 5, 2026, unless the Offer is extended or withdrawn. The Offer is intended to provide stockholders with an option for limited liquidity in the absence of a public trading market, which aligns with the Company's long-term strategic objective of providing greater stockholder liquidity. The Offer is being made pursuant to the terms set forth in the offer to purchase, dated September 4, 2026 (the "Offer to Purchase"), and the related letter of transmittal (the "Letter of Transmittal").

Under the terms of the Offer, stockholders who tender their Shares will receive the Offer Price of $33.00 per Share in cash, subject to proration if the Offer is oversubscribed.

The Offer is not conditioned upon any minimum number of Shares being tendered; however, it is contingent upon the closing of a financing, among other conditions set forth in the Offer to Purchase. Specific instructions and a complete explanation of the terms and conditions of the Offer are contained in the Offer to Purchase, the Letter of Transmittal and the related materials, which have been mailed to stockholders of record. Any Shares tendered may be withdrawn prior to expiration of the Offer.

Tender offer materials and other resources for stockholders are also available at http://investors.vinebrookhomes.com/resources/2026-tender-offer-resources.

While the Company's Board of Directors has approved the Offer, none of the Company, its Board of Directors, LODAS Transfer, LLC, in its capacity as the Depositary and Paying Agent for the Offer, RBC Capital Markets, LLC, as the Dealer Manager, nor NexPoint Securities, Inc., as the Information Agent, makes any recommendation to any stockholder as to whether to tender or refrain from tendering any Shares. The Company has not authorized any person to make any such recommendation. Stockholders must decide whether to tender their Shares and, if so, how many Shares to tender. In doing so, stockholders should carefully evaluate all of the information in the tender offer documents, when available, before making any decision with respect to the tender offer, and should consult their own broker or other financial and tax advisors.

LODAS Transfer, LLC will serve as the Depositary and Paying Agent, RBC Capital Markets, LLC will serve as the Dealer Manager and NexPoint Securities, Inc. will serve as the Information Agent for the Offer.

Additional Information Regarding the Tender Offer

This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any Shares. The solicitation and offer to buy the Company's Shares will be made only by the Offer to Purchase, the Letter of Transmittal and the related materials. Stockholders should carefully read those materials because they will contain important information, including the various terms and conditions of the Offer. The Offer to Purchase, the Letter of Transmittal and the related materials have been filed by the Company with the Securities and Exchange Commission (the "SEC") and may be obtained free of charge at the SEC's website at www.sec.gov. Stockholders may also obtain copies of these documents, without charge, from the Company's website at http://investors.vinebrookhomes.com/resources/2026-tender-offer-resources. Stockholders are urged to read these materials carefully before making any decision with respect to the tender offer.

Stockholders and investors who have questions or need assistance may contact RBC Capital Markets, LLC at (877) 381-2099 (toll-free) or (212) 905-5846 (collect) or by email at [email protected]. They may also contact LODAS Transfer, LLC, the Depositary and Paying Agent, at (833) 586-1960 (toll-free) or by email to [email protected] or NexPoint Securities, Inc., the Information Agent, at (833) 697-7253 (toll-free).

About VineBrook Homes Trust, Inc.

VineBrook Homes Trust, Inc. is an externally advised real estate investment trust. VineBrook Homes is focused on acquiring, developing, renovating, leasing and operating single-family rental home investments primarily located in large to medium size cities and suburbs located in the midwestern, heartland and southeastern United States markets. For more information, please visit investors.vinebrookhomes.com.

Forward Looking Statements

This press release includes forward-looking statements, including those related to the commencement and terms of the proposed tender offer. The words or phrases "expect," "anticipate," "estimate," "intends," and other similar expressions are intended to identify such forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. These forward-looking statements include, among others, statements with respect to the conduct, terms and completion of the tender offer and the Company's intent to provide options for limited liquidity which aligns with the Company's long-term strategic objective of providing greater stockholder liquidity. You should not rely on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect actual results, performance or achievements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, those described in greater detail in the Company's filings with the SEC, particularly those described in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers should not place undue reliance on any forward-looking statements and are encouraged to review the Company's other filings with the SEC for a more complete discussion of the risks and other factors that could affect any forward-looking statement. Except as required by law, the Company does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.

CONTACTS

Investor Relations

Kristen Griffith

[email protected]

Media Relations

[email protected]

SOURCE VineBrook Homes Trust, Inc.

Share this article

Tiger Group Auction Features Complete Vinyl Window, Patio Door and Glass Manufacturing Facility

Bidding opens Sept. 10 in sale of integrated, 180,000-square-foot plant in Greater Houston.

MISSOURI CITY, Texas, Sept. 8, 2026 /PRNewswire/ -- Tiger Group will conduct an online auction featuring vinyl window, patio door and insulating-glass manufacturing equipment and inventory from Showcase Window and Door Company, a longtime manufacturer serving residential new-construction and replacement markets.

The timed, online auction opens on Thurs., Sept. 10, at 10 a.m. (CT) and closes on Thurs., Sept. 17, at 10 a.m. (CT) at SoldTiger.com.

The assets are located in a more than 180,000-square-foot manufacturing and inventory facility in Missouri City, Texas, in the Greater Houston area. The equipment is from leading North American and European manufacturers, including Greller, Stürtz, GED, Hegla, Yilmaz, Joseph Machine, Pro-Line, Bilco and Haeco.

"This represents one of the most comprehensive window-and-door asset offerings we've seen in recent years," said Chad Farrell, senior managing director of Tiger Commercial & Industrial, a division of Tiger Group. "It's an opportunity to acquire complete, production-ready manufacturing systems rather than individual machines alone. Bidders will find multiple vinyl window production lines, a dedicated patio door line, a complete insulating-glass line, substantial finished and work-in-process inventory, and extensive plant-support infrastructure."

Highlights of the sale include:

- 2024 Hegla Ecolam 33 Plus laminated-glass cutting table with air tables and controls.

- Complete GED insulating-glass cutting and processing line with tempering oven, extruder, conveyors and argon-filling station.

- 183 Window Production Line featuring a 2017 Greller G400SE-330 high-performance four-point vinyl window/door frame welder and related equipment.

- 262 Window Production Line featuring Pro-Line frame and sash welders, corner cleaners and glazing equipment.

- 262 Casement Production Line with Greller frame welder and Tringia cleaning system.

- Complete Patio Door Production Line with Stürtz horizontal four-point welders and CNC corner-cleaning equipment.

- Simulated Divided Lite production equipment, including end mills, a saw station and worktables.

- Significant quantities of finished and work-in-process windows, patio doors, extruded aluminum, vinyl casings, hardware and related inventory.

In addition, the sale features machine shop, maintenance and plant-support items, along with material-handling equipment, forklifts, pallet racking and glass racks, plus office furnishings. Late-model rolling stock on offer includes Great Dane dry van trailers and Chevrolet Silverado, Jeep Cherokee and Dodge Ram pickups.

Founded in 1994, Showcase Window and Door Company manufactured custom vinyl windows and patio doors for the residential new-construction and replacement markets. The Houston-based company served customers throughout Texas, Louisiana, Mississippi, Arkansas, Oklahoma, Kansas and Missouri. It was known for producing energy-efficient vinyl windows, impact-resistant window products, sliding patio doors and related building products.

For asset photos, descriptions, and other information, visit

https://soldtiger.com/sales/manufacturer-of-vinyl-windows-patio-doors/

Inspections are available on Wed., Sept. 16, from 10 a.m. to 4 p.m. (CT) in Missouri City. To arrange an inspection or obtain other information, email: [email protected] or call (805) 497-4999.

Media Contacts: At Tiger Group, Maria Hoang, (805) 497-4999, [email protected]. At Jaffe Communications, Joey Linde, (908) 789-0700, [email protected].

SOURCE Tiger Group

Share this article